News
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
2024 nominations are open for Giants of Cancer Care®
Share your views with OncChats
Specialty
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
OncClub
All Oncology News
Pipeline Report
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conference Coverage
Conference Listing
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Interactive Tools
Learning Modules
Presentations
Sponsored
Print Subscription
eNewsletter
Advertisement
Urothelial Cancer
| Breast Cancer
| Lung Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Ovarian Cancer
| Prostate Cancer
| Melanoma & Skin Cancer
| Mantle Cell Lymphoma
| Myeloproliferative Neoplasms
| Biosimilars
| Brain Cancer
| Business Management
| CAR T-cell Therapy
| COVID-19
| Chronic Lymphocytic Leukemia
| Colorectal Cancer
| Disparities in Cancer Care
| Global Oncology
| Gynecologic Oncology
| Head & Neck Cancers
| Hematologic Oncology
| Immuno-Oncology
| Multiple Myeloma
| Neoadjuvant HER2+
| Non-Hodgkin Lymphoma
| Oncology Nursing News
| Pediatric Oncology
| Precision Medicine in Oncology®
| Sarcomas/TGCT
| Supportive Care
View All >>
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
  • Business Management
  • CAR T-cell Therapy
  • COVID-19
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Global Oncology
  • Gynecologic Oncology
  • Head & Neck Cancers
  • Hematologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Mantle Cell Lymphoma
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Neoadjuvant HER2+
  • Non-Hodgkin Lymphoma
  • Oncology Nursing News
  • Ovarian Cancer
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Prostate Cancer
  • Sarcomas/TGCT
  • Supportive Care
  • Urothelial Cancer

SPOTLIGHT -

2024 nominations are open for Giants of Cancer Care®
| Share your views with OncChats

Syed Rizvi, MD

home / authors / syed-rizvi-md

Articles


Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

April 24th 2020

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Read More


Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

April 16th 2020

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Read More


Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

March 19th 2020

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Read More


Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

February 11th 2020

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

Read More

Latest Conference Coverage

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy

Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact